$SOTK

Bagley Stephen James sold $43K of SOTK

Bagley Stephen James (CFO) sold 8,346 shares of SONO TEK CORP (SOTK) at $5.13 on 2026-07-30.

Original reporting
SEC EDGAR · Bagley Stephen James
Published Aug 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:14 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SOTK
Neutral
low confidence
Mentioned
$SOTK
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOTKNeutralLow
01

Why it matters

The only new information is the disclosed insider sale size, price, and post-transaction holdings; it does not include earnings, guidance, or operational updates.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no fundamental trigger in the filing.

03

What to watch

The filing does not state motivations, and the absence of a 10b5-1 plan does not automatically imply bearish information without additional context.

Relevance 3/10Novelty 3/10Timing: filed Aug 3, 2026 for a July 30 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Sono Tek Corp.

Company-level read

Ticker impact

$SOTKNeutralLow confidence
Context

Sono Tek Corp CFO Bagley sold 8,346 shares in an open-market transaction at $5.13/share, disclosing $42,814.98 in proceeds.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

Form 4 insider sales are common and the filing provides no new company performance or guidance, only transaction details.

Market effects

No clear sector read-through from a single small insider sale.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification or personal liquidity needs and may not signal reduced confidence.

Key entities

  • Sono Tek Corp

    Company whose CFO insider sale is disclosed via Form 4.

  • Bagley Stephen James

    CFO who sold 8,346 shares in an open-market transaction.

Related articles

$SOTKMedAI 8/10

Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results

Sono-Tek (Nasdaq: SOTK) reported first-quarter fiscal 2027 results for the quarter ended May 31, 2026. Net sales rose 10% to $5.66 million, gross margin expanded to 57% from 52%, operating income increased 86% to $897,000, and net income rose to $741,000 ($0.05 diluted). Cash was $16.65 million with no debt, and backlog was $7.73 million. The company expects continued 1H growth driven by medical demand and higher-value production systems.

$SOTKMed

SONO TEK CORP (SOTK): Results of Operations and Financial Condition

SONO TEK CORP (SOTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm SONO-TEK CORPORATION REPORTS FIRST QUARTER FISCAL 2027 RESULTS Exhibit 99.1 Sono-Tek Corporation Reports First Quarter Fiscal 2027 Results Revenue Increased 10%; Gross Margin Expanded to 57%; Operating Income Increased 86%; Net Income Increased 67% Anticipati

$SOTKMedAI 9/10

Sono-Tek Corporation Q4 2026 Earnings Call Summary

Sono-Tek Corporation reported Q4 2026 results driven by a shift to higher-ASP, turnkey production systems. The company said medical demand rose 54% year over year, while clean energy orders fell 19% amid government policy changes. Gross margin increased to 51% and operating income rose 81%. Management projected growth and profitability in fiscal 2027 H1, with flat-to-modestly higher full-year revenue amid clean-energy uncertainty. Cash was $14.8 million with no debt.

$SOTKMedAI 9/10

Sono-Tek Reports Fiscal Fourth Quarter and Full Year 2026 Financial Results

Sono-Tek (Nasdaq: SOTK) reported FY2026 net sales of $20.9M (+2% YoY), gross margin of 51% (up from 47.5%), operating income of $1.82M (+81%), and net income of about $1.8M (+42%), according to the company. Q4 net sales were $5.6M (+10%). Backlog was $9.1M. The company expects continued 1H FY2027 revenue growth driven by medical and high-ASP systems; FY2027 revenue projected flat to modestly higher.